Signals
Breast Cancer Gets a New PI3K Pathway Option.
The FDA has approved gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation. The approval creates a new option, but only if mutation testing is routine and trusted.
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
AI Pathology Moves From Demo to Workflow
AlphaGenome Makes Variant Interpretation Political
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.